Nuvectis Pharma Inc (NVCT) Stock Price, Quote & News

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 614 3150

Website: www.nuvectis.com

Address:

1 Bridge Plaza, Suite 275, Fort Lee, United States

boomupwego Dec. 13 at 1:28 AM

$GOSS $NVCT $SGMO No thanks. I’ll stick with GOSS for now….

1 · Reply

mmtiddy Dec. 12 at 7:19 PM

$SGMO Sold my positions on $GOSS and $NVCT for this, $0.40 cents with their drugs on trial? I am autistic and I know this is completely undervalued to what the big dogs have been thinking

1 · Reply

mmtiddy Dec. 12 at 7:42 AM

$NVCT hehe its starting

0 · Reply

essiepaul Dec. 11 at 11:58 PM

$NVCT back in a couple of days ago. Hopefully a rally has started like a few yrs back when this ran from 6’s to high teens. Cant doubt the commitment from RB & CMM 900 hits this will be a grand slam

0 · Reply

buyandsold Dec. 4 at 10:07 PM

$NVCT this should be a$1BN company just based on potential and 5x from there on delivery. Why is it not?

2 · Reply

UNLV Dec. 4 at 3:29 PM

$NVCT stock 6.50 up from 5.80 and the initial disappointment data update pushed back Q2. Encouraging hearing OPINION LEADER talk of toxicity around current therapy and low levels of toxicity NXP900. Competition and toxicity around combo therapy has been a concern

1 · Reply

UNLV Dec. 3 at 2:58 PM

$NVCT the FDA will have lower bar to approval around NXP900 targeting unmet need where no authorized therapy other than chemotherapy is available. Also expecting NXP900 to combo with chemotherapy

1 · Reply

UNLV Dec. 3 at 2:50 PM

$NVCT most attracted to big opportunity NSCLC but big opportunity big competition. Nuvectis targeted approach also has indications including tumors targets with no authorized or effective therapy available. Breakthrough therapy, Fast Track, Accelerated Approval and much lower bar to from FDA all on the table for unmet need

0 · Reply

buyandsold Dec. 2 at 8:29 PM

$NVCT i doubled my position into today, i need to trim back now! I saw it as a free peak at a positive catalyst.

1 · Reply

BioTrade2 Dec. 2 at 2:30 PM

$NVCT that was boring. Data Q2 (maybe). That’s all I learned. Anyone else picked up any other hints/nuggets?

1 · Reply

Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC

Nov 4, 2025, 8:15 AM EST - 5 weeks ago

CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 16, 2025, 8:00 AM EDT - 2 months ago

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 4, 2025, 7:30 AM EDT - 3 months ago

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:30 PM EDT - 4 months ago

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 5, 2025, 9:57 PM EDT - 4 months ago

Nuvectis (NVCT) Q2 Loss Widens 43%

Aug 5, 2025, 7:30 AM EDT - 4 months ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 31, 2025, 7:45 AM EDT - 4 months ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

May 16, 2025, 4:35 PM EDT - 7 months ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 7 months ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 4:25 PM EDT - 8 months ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Mar 14, 2025, 8:00 AM EDT - 9 months ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 7, 2025, 8:30 AM EST - 11 months ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 6, 2025, 2:00 PM EST - 11 months ago

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback

Feb 5, 2025, 9:01 AM EST - 11 months ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 11 months ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 14, 2024, 2:23 PM EST - 1 year ago

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:28 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Feb 9, 2024, 8:32 AM EST - 2 years ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 25, 2023, 7:30 PM EDT - 2 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 10:14 AM EDT - 2 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 10, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Dec 1, 2022, 8:00 AM EST - 3 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nov 8, 2022, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 18, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

boomupwego Dec. 13 at 1:28 AM

$GOSS $NVCT $SGMO No thanks. I’ll stick with GOSS for now….

1 · Reply

mmtiddy Dec. 12 at 7:19 PM

$SGMO Sold my positions on $GOSS and $NVCT for this, $0.40 cents with their drugs on trial? I am autistic and I know this is completely undervalued to what the big dogs have been thinking

1 · Reply

mmtiddy Dec. 12 at 7:42 AM

$NVCT hehe its starting

0 · Reply

essiepaul Dec. 11 at 11:58 PM

0 · Reply

buyandsold Dec. 4 at 10:07 PM

$NVCT this should be a$1BN company just based on potential and 5x from there on delivery. Why is it not?

2 · Reply

UNLV Dec. 4 at 3:29 PM

1 · Reply

UNLV Dec. 3 at 2:58 PM

$NVCT the FDA will have lower bar to approval around NXP900 targeting unmet need where no authorized therapy other than chemotherapy is available. Also expecting NXP900 to combo with chemotherapy

1 · Reply

UNLV Dec. 3 at 2:50 PM

0 · Reply

buyandsold Dec. 2 at 8:29 PM

$NVCT i doubled my position into today, i need to trim back now! I saw it as a free peak at a positive catalyst.

1 · Reply

BioTrade2 Dec. 2 at 2:30 PM

$NVCT that was boring. Data Q2 (maybe). That’s all I learned. Anyone else picked up any other hints/nuggets?

1 · Reply

pi22dv7 Nov. 30 at 8:45 PM

$NVCT Hello investors, new here (LT AXSM, VKTX and other Bios). Appreciate some education on near term catalyst? Have very few info other than 1b readout in Q1 (and insider buys), what is expected here lets say in next 1 year and potential market/PPS opportunity. Thanks.

1 · Reply

Smellmahass Nov. 26 at 8:23 PM

$NVCT Data on Dec 2 is not primary endpoint but should still move this stock decently?

2 · Reply

UNLV Nov. 26 at 3:25 PM

$NVCT https://nuvectis.com/press-release-view/

1 · Reply

WallStWireAds Nov. 25 at 3:50 PM

$NVCT https://caplynx.io/82PwbDY

0 · Reply

BioTrade2 Nov. 19 at 1:58 AM

$NVCT some what ok with 800 discontinued. They can barely progress one program, there are some management teams that move fast. This one is average

1 · Reply

UNLV Nov. 18 at 3:41 PM

$NVCT research, preclinical data leads to starter positions. Tailing big insider buys I'm deep before 1b data

0 · Reply

NVDAMillionaire Nov. 18 at 11:36 AM

$NVCT Brilliant piece that captures NVCT's situation perfectly. So if you want to update your understanding of NVCT or get to know NVCT better, this is essential reading. https://beyondspx.com/quote/NVCT/analysis/nuvectis-pharma-unlocking-oncology-s-future-through-precision-kinase-inhibition-nasdaq-nvct

0 · Reply

BioTrade2 Nov. 17 at 2:55 AM

$NVCT I was told there was a healthcare focused fund that added nvct.

1 · Reply

BioTrade2 Nov. 14 at 3:28 AM

$NVCT affinity or exome (my guess). The specialized bio fund that bought in couple of months back. Your guess?

1 · Reply

BioTrade2 Nov. 12 at 10:06 PM

$NVCT when is everyone expecting monotherapy nxp900 efficacy data? Mid Aug they said they began the study, 15 sites. Resonable to assume 25 patients enrolled by now? Data update Q126?

1 · Reply

CEOBuysDisclosures Nov. 6 at 3:05 PM

$NVCT CEO purchased 5,000 shares at $5.72 for a total of $28,600. BENTSUR RON now owns 3,525,924 shares. https://ceo-buys.com

0 · Reply

resistancebreakers Nov. 6 at 1:47 PM

$NVCT Insiders keep on adding and adding 🔥🪖🫡☝️

1 · Reply

Market Cap	194.16M
Revenue (ttm)	0.00
Net Income (ttm)	-19.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	77,000
Avg Vol	102,164
Day's Range	N/A - N/A
Shares Out	25.62M
Stochastic %K	91%
Beta	-0.27
Analysts	Strong Sell
Price Target	$18.00